NAVB - Navidea Biopharmaceuticals, Inc.

NYSE American - NYSE American Delayed Price. Currency in USD
Show:
Income Statement
Balance Sheet
Cash Flow
Annual

Income Statement

All numbers in thousands
Breakdown
ttm
12/30/2018
12/30/2017
12/30/2016
Total Revenue
658
1,169
1,810
21,970
Cost of Revenue
29
97
4
2,297
Gross Profit
628
1,073
1,807
19,673
Operating Expenses
Research Development
4,467
4,222
4,514
8,883
Selling General and Administrative
6,553
7,698
11,170
13,014
Total Operating Expenses
11,020
11,920
15,684
21,896
Operating Income or Loss
-10,392
-10,847
-13,877
-2,223
Interest Expense
-
31
-
-
Total Other Income/Expenses Net
-1,033
-5,290
-4,082
2,776
Income Before Tax
-11,412
-16,169
-17,790
-14,309
Income Tax Expense
-74
3
-4,062
-
Income from Continuing Operations
-11,337
-16,171
-13,727
-14,309
Net Income
-11,337
-16,126
74,946
-14,308
Net Income available to common shareholders
-11,337
-16,126
74,946
-14,308
Reported EPS
Basic
-
-1.80
9.40
-1.80
Diluted
-
-1.80
9.00
-1.80
Weighted average shares outstanding
Basic
-
8,527
8,080
7,771
Diluted
-
8,527
8,301
7,771
EBITDA
-
-10,847
-13,877
-1,722